CLOV vs ALHC

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

CLOV

33.4
AI Score
VS
ALHC Wins

ALHC

48.2
AI Score

Investment Advisor Scores

CLOV

33score
Recommendation
SELL

ALHC

48score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CLOV ALHC Winner
Revenue 2.25B 1.36B CLOV
Net Income 61.77M -100.81M CLOV
Net Margin 2.7% -7.4% CLOV
Operating Income 61.77M -85.90M CLOV
ROE 15.8% -53.5% CLOV
ROA 8.2% -13.1% CLOV
Total Assets 753.68M 770.79M ALHC
Current Ratio 1.55 1.63 ALHC
Free Cash Flow 201.03M 102.88M CLOV

Relative Price Performance (Last 90 Days)

CLOV 1M: +3.3% · 3M: +10.7% ALHC 1M: -7.3% · 3M: -42.9%

Current Technical Phase

CLOV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.8% over 20 days), RSI 60

RSI (14): 59.7 · Price: $4.97

ALHC

Markdown
Sell / avoid

Price below a falling SMA50 (slope -20.1%), weak momentum, RSI 45

RSI (14): 44.7 · Price: $7.69

Fundamentals Snapshot

Metric CLOV ALHC
Market Cap — —
Forward P/E 27.6 13.9
Trailing P/E 493.0 54.8
Revenue (TTM) — —
Revenue Growth 0.5% 0.4%
Gross Margin 0.2% 0.1%
Operating Margin 0.0% 0.0%
EPS 0.01 0.14
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, ALHC is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.